Sumo Biosciences LLC was opened with the goal to develop novel therapeutics to inhibit the human oncogene, c-Myc which is a major human oncogene to contribute to at least 70% of all human cancers. Firm's initial studies are focused on colorectal cancers, because these cancers are almost 100% dependent on c-Myc and new therapies are critically needed for metastatic colorectal cancers to improve patient survival.
